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Abstract 
The endocannabinoid system is an important modulatory system of the brain. It consists of 
cannabinoid receptors type 1 and type 2 (CB1R and CB2R), the endogenous cannabinoids that bind 
to these receptors, and enzymes that synthetize and metabolize endogenous cannabinoids. The 
endocannabinoid system partakes in brain development, brain plasticity and cognitive function. It has 
also been associated with several psychiatric disorders. Previous studies conducted with human and 
animal subjects indicate that there may be gender differences in the endocannabinoid system. This 
difference has been suggested to be transmitted via gonadal hormones, especially estrogen. 
The aim of this study was to examine whether combined oral contraception has impact on brain CB1R 
availability in healthy women. Somatic diseases were ruled out by laboratory tests, EKG and somatic 
status. Psychiatric axis I disorders were ruled out by structured psychiatric interview. MRI was done 
to all subjects to rule out structural anomalities. 
PET-imaging were performed using the CB1R specific radioligand [18F]FMPEP-d2. Emission data 
was gathered first for 60 minutes, and continued for another 30 minutes after a 30 minute break. The 
activity of the radioligand and its metabolites in blood was measured using arterial blood samples. 
Continuous blood samples were taken for the first 3.5 minutes, and after that manual samples were 
drawn from the artery cannula. The radioligand activity concentrations in plasma were corrected to 
correspond to unchanged radioligand activity in each timepoint. CB1R availability was quantified 
using modeling of distribution volume with Logan plot. We used repeated measures ANOVA to test 
the difference between the groups. 
In this study we found that women who used combined oral contraception had significantly lower 
distribution volume compared to women who did not use hormonal contraception. 
Our finding supports the previous evidence of gonadal hormones affecting the endocannabinoid 
system. The phase of ovarian cycle was not known in all subjects and blood estrogen levels were not 
measured in this study. However, results indicate a need to consider hormonal pharmaceutical use 
and the hormonal status of human subjects when studying the endocannabinoid system. 
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1. Introduction  
The endocannabinoid system is a widespread neurotransmitter system of the brain. It consists of two 
main cannabinoid receptors, endocannabinoid receptors 1 and 2, the endogenous endocannabinoid 
receptor agonists 2-arachidonoylglycerol (2-AG) and N-arachidonoyl-ethanolamide or anandamide 
(AEA), and the enzymes that are responsible for the synthesis and degradation of these 
endocannabinoids (Lu et al., 2016). AEA is mostly degraded by fatty acid amide hydrolase (FAAH), 
while 2-AG is broken down by both monoacylglycerol lipase (MAGL) and FAAH. Cannabinoid 
receptors are G-protein coupled receptors serving neuromodulatory functions. Cannabinoid receptor 
type 1 (CB1R) is most abundant in the central nervous system, while the cannabinoid type 2 receptor 
(CB2R) is primarily expressed in peripheral tissues (Gorzkiewicz et al., 2018). The effect of the 
endocannabinoids on neurotransmission is mainly transmitted via the CB1 receptors (Chanda et al., 
2019), which is why the role of CB2 receptor is not discussed in this review. 
Recent  evidence suggests that the endocannabinoid system may play a part in several psychiatric 
disorders (Ibarra-Lecue et al., 2018). When compared to healthy individuals, differences in the 
endocannabinoid system have been reported in patients suffering from depression, schizophrenia, 
PTSD, anxiety diseases and some neurodegenerative diseases such as Alzheimers disease and 
Parkinsons disease (Sloan et al., 2018). However, some of the evidence is inconclusive (Ibarra-Lecue 
et al., 2018). Furthermore, in recent years the endocannabinoid system has been investigated as a 
potential target for pharmacological therapies. (Davies et al., 2019) 
Evidence from in vivo human positron emission tomography studies of CB1R is accumulating. 
However, combined sample sizes in these studies are still relatively small and heterogenous between 
studies, which hampers drawing conclusions of disease specific associations (Van Laere et al., 2008; 
Normandin et al., 2015; Laurikainen et al., 2019). For example sex and gonadal hormone status have 
been suggested to affect the results of CB1R studies (Laurikainen et al., 2019).  
 
1.1. Gender differences and the CB1 receptor 
There is evidence of gender differences in the expression of CB1 receptor in certain brain areas. In 
mice, one study showed significantly higher amounts of CB1 receptor mRNA transcripts in intact 
males compared to female rats in the anterior pituitary gland (González et al., 2000). Another study 
reported higher levels of CB1R mRNA in the cerebellum and brain stem of female mice (Xing et al., 
2011).  Higher levels of mRNA in female rats compared to males have been also reported in the 
amygdala, hippocampus and prefrontal cortex (Xing et al., 2014). Hippocampal CB1 receptor protein 
expression has been shown to be higher in male mice compared to female mice (Reich et al., 2009), 
and CB1 receptor density has been shown to be  higher in the mesencephalon and hypothalamus of 
male versus female rats (de Fonseca et al., 1994; Riebe et al., 2010). There have also been some 
reports that suggests females to have higher brain CB1 receptor density. One study reported that 
female rats have higher cannabinoid receptor protein density in the amygdala compared to males 
(Riebe et al., 2010). Zamberletti and colleagues (2012)  reported that female rats have higher overall 
expression of CB1 protein in the brain. Higher CB1 receptor protein expression has been also reported 
separately in the frontal cortex, parietotemporal cortex and thalamus of female rats compared to males 
(Takkinen et al., 2018). 
Higher overall CB1R availability in females compared to males has been reported in human in vivo 
PET studies (Neumeister et al., 2013; Normandin et al., 2015), while contradictory results showing 
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higher CB1 receptor availability in males compared to females have also been reported (Van Laere 
et al., 2008; Laurikainen et al., 2019). 
To summarize, the results regarding sex differences of the human endocannabinoid system are 
inconclusive. Methodological differences, such as the use of different radioligands and primary 
outcome measures in human PET studies, may partly explain the discordant results of the studies 
outlined above (Neumeister et al., 2013; Laurikainen et al., 2019). Further, the hormonal status of 
female subjects has been largely overlooked as a potential source of variation when measuring the 
human endocannabinoid system. 
1.2. Gonadal hormones 
The gonadal hormones estrogen, progesterone and androgens are lipophilic steroid hormones. They 
can pass the blood-brain barrier to access the central nervous system by diffusion or via specific 
transporter molecules (Banks, 2012). Neurosteroid hormones can also be synthetized in the brain 
from cholesterol and other steroidal precursors (Plassart-Schiess et al., 2001). Neurosteroids have 
their own specific nuclear and membrane associated receptors in the brain, but they also act as a 
modulators of other receptors and are thus posed to impact brain function through various 
mechanisms (Plassart-Schiess et al., 2001).  
Estrogen has been shown to associate to memory functions, mood and mental state in humans (Fink 
et al., 1996). For example, decreased levels of estrogen are associated with depression and 
premenstrual syndrome (Fink et al., 1996). Oral contraceptive use has also been suggested to affect 
the mood in some individuals (Skovlund et al., 2016). De Witt et. colleagues (2019) recently reported 
that female subjects under 16 years old using oral contraceptives scored higher in a depression 
symptom self-report scale compared to similarly aged females who were not using oral 
contraceptives.  
Gorzalka and Dang (2012) suggested that the endocannabinoid system and gonadal hormones have a 
bidirectional impact on each other. They stated that gonadal hormones seem to affect functions 
associated to the endocannabinoid system and that in addition, CB1 receptors of the brain seem to be 
abundant in brain areas which are also affected by estrogen. Furthermore, various studies imply that 
endocannabinoid system could be altered by gonadal hormone status, particularly estrogen (de 
Fonseca et al., 1994; Riebe et al., 2010).  
 
1.3. Gonadal hormones and the endocannabinoid system 
In one animal study conducted with rats, ovariectomy (OVX) resulted in decreased cannabinoid 
receptor protein density in the limbic forebrain (de Fonseca et al., 1994). This effect reported by 
Fonseca et al. was reversable by the administration of estradiol or progesterone. Further, chronic 
estradiol treatment seemed to increase the density of cannabinoid receptors in both intact females and 
ovariectomized females. (de Fonseca et al., 1994). A study conducted by Riebe et al. (2010) showed 
that OVX female rats had increased CB1R ligand binding in the hippocampus, hypothalamus and 
decreased binding in the amygdala when compared to intact females and estradiol-treated females. 
Another study found that estradiol treated OVX rats had significantly lower CB1 receptor-mRNA 
levels in the anterior pituitary gland (González et al., 2000). 
CB1 receptor expression has also been suggested to fluctuate in some brain areas throughout the 
ovarian cycle (González et al., 2000). For example, CB1 receptor mRNA transcripts measured from 
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the anterior pituitary gland fluctuated during the different phase of the ovarian cycle (González et al., 
2000). Accordingly, another study reported significant variation of cannabinoid receptor binding in 
the medial basal hypothalamus and the limbic forebrain throughout the phases of the ovarian cycle 
(de Fonseca et al., 1994). In this study, cannabinoid receptor binding was reported to be lowest during 
the estrus and highest during the diestrus (de Fonseca et al., 1994). The activity FAAH, the enzyme 
responsible for metabolizing anandamide, has been reported to be decreased by the effect of estrogen 
and progesterone in mouse uterus (Maccarrone et al., 2000), while the relocation of estrogen receptor 
alpha has been reported to downregulate the expression of the FAAH gene (Waleh et al., 2002). 
To our knowledge only one study has investigated the effects of oral contraception on CB1R binding 
(Van Laere et al., 2008). No significant differences between women using oral contraceptives 
compared to women not using oral contraceptives were found in this study. Unfortunately, the type 
of oral contraception used by the participants was not explicitly stated so it is possible that the group 
consisted of subjects using progestin contraception as well as combined contraceptives with both 
estrogen and progestin effects. These two different oral contraception methods might have a 
differential effect on the endocannabinoid system. 
 
1.4. Behavioral associations 
The behavioral effects of phytocannabinoids have been reported to have gender differences. This 
could be due to differences in gonadal hormones acting as modulators of phytocannabinoid receptor 
CB1R, but possibly also due to the developmental effects of gonadal hormones (Craft et al., 2013, 
2017). The pharmacological effects of cannabinoids which are more prominent in men include 
changes in food intake, energy homeostasis and decreased sexual behavior (Fattore et al., 2010). In 
women exogenous cannabinoids have more prominent effects in analgesia, motor activity, symptoms 
of depression, catalepsy, anxiety, and increase in sexual behavior (Fattore et al., 2010). 
In animal studies the antinociceptive effects of Δ9-tetrahydrocannabinoid (THC), the primary 
psychoactive compound of phytocannabinoids, has been reported to be dependent on gonadal 
hormone status (Wakley et al., 2011; Craft et al., 2017). Estrogen increases the antinociceptive effects 
of THC in males (Craft et al., 2017) and OVX females (Craft et al., 2008), while it does not enhance 
antinociceptive effects in hormonally intact females (Craft et al., 2017). There is also support for 
gonadal hormone involvement in modulation of fear responses based on reports that fear responses 
of OVX rats were increased compared to intact females (Simone et al., 2015). However, since 
estrogen replacement therapy did not affect the responses of the OVX rats the response doesn’t seem 
to be directly estrogen dependent. The same study also reported that the fear modifying effect of 
agonist or antagonist action on the CB1 receptor was not affected by estrogen. (Simone et al., 2015).  
The estrogen system seems to be affected by the endocannabinoid system. This has been speculated 
to be caused by the central downregulation of luteinizing hormone (LH) and gonadotropin releasing 
hormone (GnRH) expression (Gorzalka et al., 2012) via endocannabinoid effects on the 
hypothalamus (Tasker et al., 2015). THC administration has been documented to decrease the amount 
of LH in brain in ovariectomized rats (Tyrey, 1978). 
Out of the gonadal hormones estrogen has been most convincingly shown to affect the 
endocannabinoid system. However, progesterone has been also reported to upregulate the FAAH 
enzyme in human lymphocytes (Maccarrone et al., 2001, 2003). The implication of gonadal hormone 
actions in human endocannabinoid system remain unclear. Therefore, in this study, we examine how 
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combined oral contraceptive pills affect the binding in CB1R. We compared the availability of CB1R 
in 18-40 year old men, similarly aged women using combined oral contraceptive pills and women 
with no contraception using positron emission tomography and the specific CB1R radioligand 
[18F]FMPEP-d2. 
 
2. Methods 
We expanded the previously published (Laurikainen et al., 2019) study sample of 11 healthy males 
and 11 healthy females to include more females using combined contraceptive pill and females 
without contraception. Recruitment of subjects was done from the national population registry, local 
educational institutions, and by local newspaper advertisement. Inclusion and exclusion criteria were 
the as in the study by Laurikainen et al. (2019). Namely, current somatic and lifetime psychiatric 
illnesses were ruled out by medical examination, blood and urine tests, electrocardiography, and a 
structured clinical interview for DSM-IV axis I disorders (SCID-I/NP). Lifetime cannabis use was 
documented, and current use was ruled out with a urine screen prior to the PET scan. Subjects with a 
lifetime substance-related disorder, DSM-IV Axis I diagnosis, or who had used any illicit substances 
two months prior to scanning, were excluded. Pregnancy was ruled out by urine and/or blood 
screening. Structural abnormalities were ruled out in all subjects with a structural MRI using the 
Philips 3T Ingenuity PET/MR hybrid scanner. 
Synthesis of [18F]FMPEP-d2, positron emission tomography, plasma input curve preprocessing, ROI 
definition and tissue activity curve measurements were done as described previously in Laurikainen 
et al. (2019). Briefly, the subjects were given an intravenous bolus injection of CB1 receptor specific 
radioligand [18F]FMPEP-d2. Emission data was gathered with the brain-dedicated high-resolution 
research tomograph in two parts (60 +30 min) so that the total scan range was 0-120 min. Emission 
data was reconstructed and head motion was corrected. The MR image was processed with freesurfer 
(http://surfer.nmr.mgh.harvard.edu/). The resulting individualized anatomical atlas was coregistered 
to the sum of the realigned PET frames. This atlas was then used to extract masks to define volumes 
of interest (VOI) on the PET time series. Mean time activity curves were gathered from 17 volumes-
of-interest (amygdala, anterior cingulate cortex, brainstem, caudate nucleus, cerebellum, frontal 
cortex, hippocampus, insula, occipital cortex, orbitofrontal cortex, parahippocampal gyrus, parietal 
cortex, posterior cingulate cortex, prefrontal cortex, putamen, temporal cortex and thalamus). 
 
Blood data analysis was done as described in Laurikainen et al. (2019). After tracer injection, the 
activity of whole blood was measured first for 3.5 minutes continuously using Allogg ABSS on-line 
detector and after that with manual arterial plasma samples at 4.5, 7.5, 11,15, 20, 25, 30, 35, 40, 45, 
50 and 60 minutes. Plasma metabolite samples were also manually drawn from artery cannula at 4.5, 
11, 15, 20, 30, 45 and 60 minutes. Plasma activity was corrected for the amount of unchanged tracer 
activity in plasma in each time point. The resulting plasma activity concentration curve was used for 
modeling. In one test subject the first measurement of radioactive metabolites was unsuccessful, thus 
the population mean was used to replace it. 
Tissue time activity curves were visually inspected for quality. In Laurikainen et al. (2019) there were 
no differences between hemispheric distribution volume measurements. Thus, the volumes of interest 
containing both hemispheres were used for statistical testing. 
 
2.1. Statistics 
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Regional [18F]FMPEP-d2 VT was calculated using Logan plot. Modeling was done with PMOD 3.4 
software (PMOD Technologies, Zurich, Switzerland) using Poisson weighting of residuals. Statistics 
were performed using IBM SPSS Statistics software. We used Shapiro-Wilks test to test the normality 
assumption of variables. Normality was not met in the putamen, pallidum, orbitofrontal cortex, 
anterior cingulate cortex and nucleus caudatus, and therefore these areas were not included in the 
parametric statistical tests. Repeated measures ANOVA was used to test the difference between the 
three groups.  
 
3. Results 
All subjects were of Finnish ancestry. No significant differences were found in smoking status, 
handedness, age, years of education, average movement during the PET scan or injected tracer 
activity. BMI did not differ between male and female subjects or between women who were on oral 
combined contraceptives and women who were not using any contraception. Lifetime cannabis use 
was greater in men (p=0.037) but cannabis use during the year preceding PET scanning did not differ 
between men and women (p=0.063). Lifetime cannabis use did not differ between the female study 
groups, and none of the female subjects had used cannabis in past year prior the PET imaging. 
 
Table 1. Demographics of male and female 
subjects 
 Male Female  p-value 
Age (years) 27.3±5.9 24.7±5.1 
 
0.198 
BMI (kg m-2) 25.3±3.74 23.4±2.49 0.259 
Years of education 15.7±3.17 
 
15.5±2.86 
 
0.959 
AUDIT score 9.09±5.87 
 
5.14±3.42 
 
0.066 
Tobacco smokers 
(N) 
1 1 0.677 
Lifetime cannabis 
use >5 times 
3 0 0.037 
Past year cannabis 
use < 6 times 
3 0 0.063 
Injected 
[18F]FMPEP-d2 
activity (MBq) 
199.6±13.00 206.1±11.40 0.134 
Average frame-to-
frame movement 
(mm) 
0.545±0.225 0.471±0.177 0.354 
Values are number or mean±standard deviation. BMI = body mass 
indeks. AUDIT = alcohol use disorders identification test. P-values 
shown are counted using non parametric tests expect in average 
movement where t-test was made.
Table 2. Demographics of female subjects. 
 Female 
without 
contraception 
Female with 
contraception 
p-value 
Age (years) 25.0-±6.98 
 
24.4±3.11 0.613 
BMI (kg m-2) 23.7±3.1 23.2±2.1 0.955 
Years of education 15.9±2.98 
 
15.2±2.90 
 
0.397 
AUDIT score 15.16±3.49 
 
5.13±3.60 
 
0.755 
Tobacco smokers (N) 1 0 0.467 
Lifetime cannabis use 
>5 times 
0 0 - 
Past year cannabis use 
< 6 times 
0 0 - 
Injected [18F]FMPEP-
d2 activity (MBq) 
202.0±13.91 209.8±7.87 0.232 
Average frame-to-
frame movement 
(mm) 
0.558±0.118 0.394±0.191 0.072 
Values are number or mean±standard deviation. BMI = body mass 
indeks. AUDIT = alcohol use disorders identification test. P-values 
shown are counted using non parametric tests expect in average 
movement where t-test was made. 
 
 
3.1. Volume of interest analysis 
We found a significant difference in VT between women who were on oral combined contraceptives 
and women who were not using any contreception (df=1, F=6.514, p= 0.024). The effect was 
regionally selective (VOI*oral contraception interaction: df= 2.447, F=5.193, p = 0.008). The VT of 
CB1R was significantly higher (p=0.024) in women who did not use combined oral contraception 
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with regionally specific effects (p=0.008). The effect was largest in the prefrontal cortex (η2= 0.403, 
t=2.965, p=0.011), frontal cortex (η2= 0.380, t=2.820, p=0.014), posterior cingulate cortex (η2= 0.359, 
t=2.700, p=0.018) and parietal cortex (η2= 0.356, t=2.678, p=0.019). 
We also tested the difference of VT between male and female subjects. Similarly to the results reported 
in Laurikainen et al (2019), a significant difference could be observed between men and women (df 
=1, F=7.11, p=0.013). The male subjects had significantly higher VT compared to females with 
combined contraception in all brain areas (df=1, F=14.873, p=0.001) and the effect was regionally 
selective (df=2.165, F=8.316, p=0.001). The effect was largest in the occipital cortex (η2=0.502, t=-
4.140, p=0.001), parietal cortex (η2= 0.502, t=-4.140, p=0.001), posterior cingulate cortex (η2=0.507, 
t=-4.180, p=0.001), prefrontal cortex (η2= 0.496, t=-4.089, p=0.001) and frontal cortex (η2= 0.474, 
t=-3.916, p=0.001). However, when female subjects without oral contraception were compared to 
males, the difference was not significantly different (df=1, F=0.909, p=0.355). 
 
4. Discussion 
Cannabinoid receptor type 1 availability was significantly lower in females who were using combined 
oral contraception compared to women who did not have hormonal contraception. These findings are 
consistent with previous reports of the effect of gonadal hormones on regulation of the CB1 receptor 
expression in the brain. Females without oral contraception did not differ in CB1 availability from 
male subjects. Therefore, the previously reported difference of CB1R availability between females 
and males could be driven by the female subjects who were using combined oral contraception. This 
can also be one of the explanations to why the results of human studies concerning sex difference in 
CB1R availability have been inconsistent since most studies haven’t accounted for the hormonal 
status of female subjects.  
The endocannabinoid system has been associated to modulation of cognitive functions. Also oral 
contraceptive use seems to also affect cognitive test performance (Gogos et al., 2014). For instance, 
improved memory task performance and visual object recognition after treatment with estradiol has 
been reported in animal studies using ovariectomized rats (Bimonte et al., 1999; Luine et al., 2003; 
Lewis et al., 2008). A study using OVX monkeys reported enhanced visuospatial attention after 
estrogen treatment (Voytko, 2002). However, the effect can be task selective as indicated by a study 
reporting that face recognition of ovariectomized rhesus monkeys was impaired by admission of 
ethinylestradiol (Lacreuse et al., 2003). 
In humans sex hormones seem to affect verbal memory performance of freely cycling premenopausal 
women. For instance, better verbal memory was observed in the high estrogen period of the 
menstruation cycle compared to the other phases of the menstrual cycle (Maki et al., 2002; Rosenberg 
et al., 2002). Oral contraceptive users have also been found to develop the conditional eyeblink 
response quicker compared to the non-users in a classically conditioned eyeblink test (Beck et al., 
2008; Holloway et al., 2011), and to have enhanced verbal memory in the active pill phase compared 
to the inactive pill phase when assessed with the California Verbal Learning Test (Mordecai et al., 
2008). However, in this study by Mordecai et al. verbal memory performance did not differ 
throughout the menstrual cycle phases of normally cycling females. 
One study compared the recall of emotional memory of a story between naturally cycling women and 
women using hormonal contraception.  The authors found that women using hormonal contraception 
had better memory of the story gist but could not recall as many details in the emotional compared 
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with neutral story conditions. Women without hormonal contraception had better memory of details 
but not the gist in the emotional compared with neutral story conditions (Nielsen et al., 2011) This is 
particularly interesting since it has been speculated that endocannabinoid system plays a regulatory 
role in consolidation of emotional memories (Ney et al., 2018). 
Studies about mood changes associated with oral contraceptive (OC) use are inconsistent. There are 
reports of OC use improving the mood in most women (Oinonen et al., 2002), but also some evidence 
about them increasing depression and anxiety (Robinson et al., 2004; De Wit et al., 2019). However, 
in most studies women have been allowed to make the choice to continue using OCs, which might 
lead to overemphasizing of benificial mood changes, since women who have experienced negative 
effects could have stopped using OCs (Oinonen et al., 2002). 
Evidence supporting regulation of mood and anxiety by the endocannabinoid system have also been 
reported. Cannabinoid receptors are populous in brain areas associated to emotional state processing, 
such as the amygdala, hippocampus and limbic areas (Ashton et al., 2011). They also seem to be 
involved in the regulation of emotional states (Witkin et al., 2005). It has been suggested that the 
endocannabinoid system in the prefrontal cortex may have a critical role in shaping the prelimbic 
circuits during stress (Worley et al., 2018). 
Altogether the currently available evidence suggests that estrogen has domain specific but not global 
effects on cognitive functions (Gogos et al., 2014) and regulation of emotional states (Ashton et al., 
2011). Since the endocannabinoid system is also known to regulate these functions it is well poised 
to mediate the effects of estrogen. In our study the largest difference between CB1R availability in 
contraceptive users compared to non-users was on frontoparietal cortices, such as the prefrontal 
cortex which is involved in inhibiting distracting information, planning, making decisions and 
working memory (Shanmugan et al., 2014).  
Oral combined contraception might also affect the structure of certain brain areas. A study conducted 
by Plezer et al (2010) reported significantly larger prefrontal cortices, pre- and postcentral gyri, 
parahippocampal and fusiform gyri and temporal regions in women using hormonal contraceptives 
compared to women not using contraceptives. Another study found that gray matter volume was 
larger in the right mid-frontal gyrus of the females using combined oral contraceptives (De Bondt et 
al., 2013).  
It is noteworthy that the estrogen used almost predominantly in combined oral contraceptives is 
ethinylestradiol, which is a synthetic form of the endogenous E2 hormone (Gogos et al., 2014). 
Ethinylestradiol has been found to be unable to convert to E1 or other weaker estrogen, which makes 
it more potent compared to endogenous E2 (Gogos et al., 2014). Estrogen and progesterone both have 
a negative feedback system through which endogenous hormone levels can be suppressed in women 
using combined oral contraceptives (Mordecai et al., 2008). It is also important to remark that oral 
contraceptives have also been found to reduce the blood levels of testosterone (Zimmerman et al., 
2014), which also might have additional impacts on brain function and structure. These differences 
illustrate how hormonal contraception pills could have different impact on the brain compared to 
endogenous estrogens and progesterone. 
The progesterone component in combined oral contraceptive pills is another factor which might affect 
the results of human studies of oral contraceptives. There are different generations of progestins, 
some with anti-androgenic properties and some with androgenic properties. There is some evidence 
that the varying progestins used in OC pills might have different effects on the brain. One study 
reported that androgenic progestin users performed worse in verbal fluency task when compared to 
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anti-androgenic progestine users and normally cycling women (Griksiene et al., 2011). 
Unfortunately, the blood levels of progestines used in combined oral contraception pills were not 
measured in this study and therefore no further analysis can be made about the role of progestines in 
the variability of CB1R availability. 
Another limitation of this study is the small group sizes, which predisposes to type II error and limits 
generizability of the results. The estrogen blood levels of the female subjects were not measured, so 
the associations estrogen levels to CB1R availability could not be studied. Further, the phase of 
ovarian cycle was not documented in all female subjects so further analysis could not be performed.  
 
5. Conclusions 
We found significantly lower CB1R availabilities in females who used oral combined contraception 
compared to females without contraception. A difference between male and female subject CB1R 
availability was observed, but there was no significant difference between male subjects and women 
who were not using oral contraception. Therefore, the difference between men and women seems to 
be driven by results from the women using combined oral contraception. These results indicate a need 
to consider hormonal pharmaceutical use and the hormonal status of human subjects when studying 
the endocannabinoid system. 
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